Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19960346rdf:typepubmed:Citationlld:pubmed
pubmed-article:19960346lifeskim:mentionsumls-concept:C0007600lld:lifeskim
pubmed-article:19960346lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:19960346lifeskim:mentionsumls-concept:C0025500lld:lifeskim
pubmed-article:19960346lifeskim:mentionsumls-concept:C0162638lld:lifeskim
pubmed-article:19960346lifeskim:mentionsumls-concept:C1512505lld:lifeskim
pubmed-article:19960346lifeskim:mentionsumls-concept:C1514526lld:lifeskim
pubmed-article:19960346lifeskim:mentionsumls-concept:C0599894lld:lifeskim
pubmed-article:19960346lifeskim:mentionsumls-concept:C0205263lld:lifeskim
pubmed-article:19960346lifeskim:mentionsumls-concept:C1521840lld:lifeskim
pubmed-article:19960346lifeskim:mentionsumls-concept:C1174739lld:lifeskim
pubmed-article:19960346pubmed:issue3lld:pubmed
pubmed-article:19960346pubmed:dateCreated2010-6-16lld:pubmed
pubmed-article:19960346pubmed:abstractTextThoracic malignancies and human breast cancer (HBC) continue to be aggressive solid tumors that are poor responders to the existing conventional standard chemotherapeutic approaches. Malignant pleural mesothelioma (MPM) is an asbestos-related tumor of the thoracic pleura that lacks effective treatment options. Altered ubiquitin proteasome pathway is frequently encountered in many malignancies including HBC and MPM and thus serves as an important target for therapeutic intervention strategies. Although proteasome inhibitor Velcade (Bortezomib) has been under clinical investigation for a number of cancers, limited preclinical studies with this agent have thus far been conducted in HBC and MPM malignancies.lld:pubmed
pubmed-article:19960346pubmed:languageenglld:pubmed
pubmed-article:19960346pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19960346pubmed:citationSubsetIMlld:pubmed
pubmed-article:19960346pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19960346pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19960346pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19960346pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19960346pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19960346pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19960346pubmed:statusMEDLINElld:pubmed
pubmed-article:19960346pubmed:monthAuglld:pubmed
pubmed-article:19960346pubmed:issn1432-0843lld:pubmed
pubmed-article:19960346pubmed:authorpubmed-author:WangYingYlld:pubmed
pubmed-article:19960346pubmed:authorpubmed-author:LonardoFulvio...lld:pubmed
pubmed-article:19960346pubmed:authorpubmed-author:PassHarvey...lld:pubmed
pubmed-article:19960346pubmed:authorpubmed-author:RuckdeschelJo...lld:pubmed
pubmed-article:19960346pubmed:authorpubmed-author:SharmaSunitaSlld:pubmed
pubmed-article:19960346pubmed:authorpubmed-author:YangHuanjieHlld:pubmed
pubmed-article:19960346pubmed:authorpubmed-author:DouQ PingQPlld:pubmed
pubmed-article:19960346pubmed:authorpubmed-author:WaliAnilAlld:pubmed
pubmed-article:19960346pubmed:authorpubmed-author:RishiArun KAKlld:pubmed
pubmed-article:19960346pubmed:authorpubmed-author:TarcaAdiAlld:pubmed
pubmed-article:19960346pubmed:authorpubmed-author:Puliyappadamb...lld:pubmed
pubmed-article:19960346pubmed:issnTypeElectroniclld:pubmed
pubmed-article:19960346pubmed:volume66lld:pubmed
pubmed-article:19960346pubmed:ownerNLMlld:pubmed
pubmed-article:19960346pubmed:authorsCompleteYlld:pubmed
pubmed-article:19960346pubmed:pagination455-66lld:pubmed
pubmed-article:19960346pubmed:dateRevised2011-2-7lld:pubmed
pubmed-article:19960346pubmed:meshHeadingpubmed-meshheading:19960346...lld:pubmed
pubmed-article:19960346pubmed:meshHeadingpubmed-meshheading:19960346...lld:pubmed
pubmed-article:19960346pubmed:meshHeadingpubmed-meshheading:19960346...lld:pubmed
pubmed-article:19960346pubmed:meshHeadingpubmed-meshheading:19960346...lld:pubmed
pubmed-article:19960346pubmed:meshHeadingpubmed-meshheading:19960346...lld:pubmed
pubmed-article:19960346pubmed:meshHeadingpubmed-meshheading:19960346...lld:pubmed
pubmed-article:19960346pubmed:meshHeadingpubmed-meshheading:19960346...lld:pubmed
pubmed-article:19960346pubmed:meshHeadingpubmed-meshheading:19960346...lld:pubmed
pubmed-article:19960346pubmed:meshHeadingpubmed-meshheading:19960346...lld:pubmed
pubmed-article:19960346pubmed:meshHeadingpubmed-meshheading:19960346...lld:pubmed
pubmed-article:19960346pubmed:meshHeadingpubmed-meshheading:19960346...lld:pubmed
pubmed-article:19960346pubmed:meshHeadingpubmed-meshheading:19960346...lld:pubmed
pubmed-article:19960346pubmed:meshHeadingpubmed-meshheading:19960346...lld:pubmed
pubmed-article:19960346pubmed:meshHeadingpubmed-meshheading:19960346...lld:pubmed
pubmed-article:19960346pubmed:meshHeadingpubmed-meshheading:19960346...lld:pubmed
pubmed-article:19960346pubmed:meshHeadingpubmed-meshheading:19960346...lld:pubmed
pubmed-article:19960346pubmed:meshHeadingpubmed-meshheading:19960346...lld:pubmed
pubmed-article:19960346pubmed:meshHeadingpubmed-meshheading:19960346...lld:pubmed
pubmed-article:19960346pubmed:meshHeadingpubmed-meshheading:19960346...lld:pubmed
pubmed-article:19960346pubmed:meshHeadingpubmed-meshheading:19960346...lld:pubmed
pubmed-article:19960346pubmed:meshHeadingpubmed-meshheading:19960346...lld:pubmed
pubmed-article:19960346pubmed:year2010lld:pubmed
pubmed-article:19960346pubmed:articleTitleTargeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines.lld:pubmed
pubmed-article:19960346pubmed:affiliationJohn D. Dingell VA Medical Center, Karmanos Cancer Institute, Wayne State University, VAMC, 4646 John R., Detroit, MI, 48201, USA.lld:pubmed
pubmed-article:19960346pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:19960346pubmed:publicationTypeResearch Support, U.S. Gov't, Non-P.H.S.lld:pubmed
pubmed-article:19960346pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed